Chemotherapy Induced Peripheral Neuropathy Market Global Report 2028

Chemotherapy Induced Peripheral Neuropathy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Steroids, Antidepressants, Anti-Seizure, and Narcotics) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy) 

  • Report Code : TIPRE00028941
  • Category : Life Sciences
  • Status : Published
  • No. of Pages : 151
Buy Now

Chemotherapy Induced Peripheral Neuropathy Market Global Report 2028

Buy Now

[Research Report] The chemotherapy induced peripheral neuropathy market is projected to reach US$ 1,174.26 million by 2028 from US$ 813.48 million in 2021; it is expected to register a CAGR of  5.4% from 2021 to 2028.

Chemotherapy-induced peripheral neuropathy is one of the most frequent side effects caused by antineoplastic agents. Clinically, it is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, chemotherapy-induced peripheral neuropathy constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing it; moreover, the possibilities of treating this syndrome are limited.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Chemotherapy Induced Peripheral Neuropathy Market: Strategic Insights

chemotherapy-induced-peripheral-neuropathy-market
Market Size Value inUS$ 813.48 Million in 2021
Market Size Value byUS$ 1,174.26 Million by 2028
Growth rateCAGR of 5.4% from 2021 to 2028
Forecast Period2021-2028
Base Year2021
Analyst Image

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

The report offers insights and in-depth analysis of the chemotherapy induced peripheral neuropathy (CIPN) market emphasizing market trends, technological advancements, and market dynamics. It also provides the competitive landscape analysis of leading market players across the world. Furthermore, the report includes the impact of the COVID-19 pandemic on the chemotherapy induced peripheral neuropathy market across all the regions. The pandemic has created both a public health crisis and an economic crisis worldwide. The global market for chemotherapy induced peripheral neuropathy before the pandemic was constantly growing owing to regularity of cancer screening, consultations, and treatments. The first wave of COVID-19 disrupted the consultations, follow-ups, and screenings of oncological cases. Moreover, disruptions in clinical trials and drug supply to patients during the early stage of the COVID-19 pandemic impacted the most crucial areas of the chemotherapy induced peripheral neuropathy market. A shift in focus to the prompt treatment of COVID-19 led to negligence toward various other medical conditions. In addition, the decrease in the detection of cancer cases and chemotherapy sessions for treatment hampered the demand for chemotherapy induced peripheral neuropathy diagnoses and treatments.  

Market Insights

Increasing Prevalence of Cancer Drives Chemotherapy Induced Peripheral Neuropathy Market Growth

Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer was reported as the first leading cause of death in the people of age below 70 years in 183 countries and the fourth leading cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types caused ~10 million deaths in 2020.

World’s Most Prevalent Forms of Cancer, 2020

   Inquire for Discount   
  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

The increasing prevalence of cancer has created a burden on healthcare systems across the world, along with bolstering the demand for chemotherapy. Chemotherapy-induced peripheral neuropathy is a common adverse effect of neurotoxic anticancer drugs, such as platinum-derivative drugs (cisplatin and oxaliplatin), spindle poisons [taxanes (paclitaxel and docetaxel), vinca alkaloids, vincristine, epothilones, and eribulin], bortezomib, and thalidomide. The high prevalence of chemotherapy-induced peripheral neuropathy raises concerns about cancer patients and survivors, and their healthcare providers, especially because there is no single effective way to prevent this condition.

In a study conducted by “The Journal of the International Association for the Study of Pain,” chemotherapy-induced peripheral neuropathy prevalence was reported at 68.1% (57.7–78.4 when measured in the first month after chemotherapy, 60.0% (36.4–81.6) in the third month, and 30.0% (6.4–53.5) in the sixth month or later. Thus, the growing incidence of chemotherapy-induced peripheral neuropathy with the increasing prevalence of cancer boosts the growth of the chemotherapy-induced peripheral neuropathy market.

Drug Class-Based Insights

Based on drug class, the chemotherapy induced peripheral neuropathy market is segmented into steroids, antidepressants, anti-seizure, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure segment is expected to register the fastest CAGR of 6.2% during the forecast period.  

Distribution Channel-Based Insights

Based on distribution channel, the chemotherapy induced peripheral neuropathy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2021, the hospital pharmacy segment held the largest share of the market. Further, the retail pharmacy segment is expected to report the highest CAGR of 5.9% during 2021–2028.

The chemotherapy induced peripheral neuropathy (CIPN) market players focus on adopting organic strategies such as product launch and expansion to expand their footprint and product portfolio worldwide, as well as to meet the growing demands.

Chemotherapy Induced Peripheral Neuropathy Market Report Scope

By Geography

Based on geography, the chemotherapy induced peripheral neuropathy market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Company Profiles

  • Regenacy Pharmaceuticals, Inc.
  • Asahi Kasei Pharma Corporation
  • Novaremed
  • Makscientific, Llc
  • Wex Pharmaceuticals Inc.
  • Sova Pharmaceuticals, Inc.
  • Kineta, Inc.
  • Aptinyx Inc.
  • Apexian Pharmaceuticals, Inc.
  • Winsantor, Inc.    
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Drug Class, and Distribution Channel

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States

Frequently Asked Questions

Who are the major players in market the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market majorly consists of the players such as Regenacy Pharmaceuticals, Inc, Asahi Kasei Pharma Corporation., Novaremed, Makscientific, Llc, Wex Pharmaceuticals Inc., Sova Pharmaceuticals, Inc., Kineta, Inc., Aptinyx Inc., Apexian Pharmaceuticals, Inc., and Winsantor, Inc. amongst others.

What is the chemotherapy induced peripheral neuropathy market?

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent side effects caused by antineoplastic agents. Clinically, CIPN is a mostly sensory neuropathy that may be accompanied by motor and autonomic changes of varying intensity and duration. Due to its high prevalence among cancer patients, CIPN constitutes a major problem for both cancer patients and survivors as well as for their health care providers, especially because, at the moment, there is no single effective method of preventing CIPN; moreover, the possibilities of treating this syndrome are very limited.

Which segment is dominating the chemotherapy induced peripheral neuropathy market?

The chemotherapy induced peripheral neuropathy market, by drug class, is bifurcated into steroids, antidepressants, anti-seizure medicines, and narcotics. In 2021, the steroids segment held the largest share of the market. The anti-seizure medicines segment of the chemotherapy induced peripheral neuropathy market is expected to witness growth in its demand at the fastest CAGR during the forecast period.

What are the driving factors for the chemotherapy induced peripheral neuropathy market across the country?

The factors that are driving and restraining factors that will affect the chemotherapy induced peripheral neuropathy market in the coming years. Major factors driving the market growth include the increasing prevalence of cancer and increasing preference for chemotherapy. Additionally, the growing clinical trials for chemotherapeutic drugs is likely to emerge as a significant future trend in the market during the forecast period. However, lack of consolidated guidelines for chemotherapy hamper the chemotherapy induced peripheral neuropathy market growth.

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Market – By Drug Class

1.3.2 Global Chemotherapy Induced Peripheral Neuropathy Market – By Distribution Channel

1.3.3 Global Chemotherapy Induced Peripheral Neuropathy Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Chemotherapy Induced Peripheral Neuropathy Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East And Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Chemotherapy Induced Peripheral Neuropathy Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Cancer

5.1.2 Increasing Preference for Chemotherapy

5.2 Market Restraints

5.2.1 Lack of Consolidated Guidelines for Chemotherapy

5.3 Market Opportunities

5.3.1 Emerging Markets in Developing Countries

5.4 Future Trends

5.4.1 Rising Clinical Trails for Chemotherapeutic Drugs

5.5 Impact Analysis

6. Chemotherapy Induced Peripheral Neuropathy Market– Global Analysis

6.1 Global Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis

6.1.1 Global Chemotherapy Induced Peripheral Neuropathy Market Revenue Forecast And Analysis

6.1.2 Global Chemotherapy Induced Peripheral Neuropathy Market – Market Potential Analysis, By Region

6.2 Market Positioning Analysis Of Key Players In Chemotherapy Induced Peripheral Neuropathy Market

6.2.1 Company Analysis

6.2.2 Growth Strategy Analysis

6.2.3 Performance Of Key Players

6.2.3.1 Wex Pharmaceuticals Inc.

6.2.3.2 Regenacy Pharmaceuticals, Inc.

7. Global Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts To 2028– by Drug Class

7.1 Overview

7.2 Drug Class Market Revenue and Forecast Analysis (US$ Mn)

7.3 Steroids

7.3.1 Overview

7.3.2 Steroids Revenue and Forecast to 2028 (US$ Mn)

7.4 Antidepressants

7.4.1 Overview

7.4.2 Antidepressants Revenue and Forecast to 2028 (US$ Mn)

7.5 Anti-seizure. Error! Bookmark not defined.

7.5.1 Overview

7.5.2 Anti-seizure Revenue and Forecast to 2028 (US$ Mn)

7.6 Narcotics

7.6.1 Overview

7.6.2 Narcotics Revenue and Forecast to 2028 (US$ Mn)

8. Global Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Analysis and Forecast to 2028 – by Distribution Channel

8.1 Overview

8.2 Distribution Channel Market Revenue and Forecast Analysis (US$ Mn)

8.3 Hospital Pharmacy

8.3.1 Overview

8.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

8.4 Retail Pharmacy

8.4.1 Overview

8.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

8.5 Online Pharmacy

8.5.1 Overview

8.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9. Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 – Geographical Analysis

9.1 North America: Chemotherapy Induced Peripheral Neuropathy Market

9.1.1 Overview

9.1.2 North America: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.3 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.4 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.1.5 North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

9.1.5.1 US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.1 US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.1.2 US: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.5.1.3 US: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.1.5.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.1 Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.2.2 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.5.2.3 Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.1.5.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.1 Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.1.5.3.2 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.1.5.3.3 Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2 Europe: Chemotherapy- Induced Peripheral Neuropathy Market

9.2.1 Overview

9.2.2 Europe: Chemotherapy- Induced Peripheral Neuropathy Market - Revenue and Forecast to 2028 (US$ Million)

9.2.3 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.4 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5 Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

9.2.5.1 Germany: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.1 Germany: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.1.2 Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.1.3 Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.2 France: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.1 France: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.2.2 France: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.2.3 France: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.3 UK: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.1 UK: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.3.2 UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.3.3 UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.4 Italy: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.1 Italy: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.4.2 Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.4.3 Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.5 Spain: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.1 Spain: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.5.2 Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.5.3 Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.2.5.6 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.1 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.2.5.6.2 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class, 2019–2028 (US$ Million)

9.2.5.6.3 Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel, 2019–2028 (US$ Million)

9.3 Asia Pacific: Chemotherapy- Induced Peripheral Neuropathy Market

9.3.1 Overview

9.3.2 Asia Pacific Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.3 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.4 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5 Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Country (%)

9.3.5.1 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.1.1 Overview

9.3.5.1.2 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.1.3 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.1.4 Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.2 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.2.1 Overview

9.3.5.2.2 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.2.3 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.2.4 China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.3 India Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.3.1 Overview

9.3.5.3.2 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.3.3 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.3.4 India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.4 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.4.1 Overview

9.3.5.4.2 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.4.3 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.4.4 South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.3.5.5 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.5.1 Overview

9.3.5.5.2 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

9.3.5.5.3 Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.5.4 Australia: Chemotherapy Induced Peripheral Neuropathy Market, by Sub-Drug Class, 2019–2028 (US$ Million)

9.3.5.6 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.3.5.6.1 Overview

9.3.5.6.2 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

9.3.5.6.3 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

9.3.5.6.4 Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

9.4 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market

9.4.1 Overview

9.4.2 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Product (US$ Million)

9.4.4 Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

9.4.5 Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Country (%)

9.4.5.1 UAE: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.1.1 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.1.2 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.1.3 UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

9.4.5.2 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.2.1 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.2.2 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.2.3 Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

9.4.5.3 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.3.1 South Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.3.2 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.3.3 South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

9.4.5.4 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.4.1 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

9.4.5.4.2 Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

9.4.5.4.3 Rest of Middle East & Africa: D Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

9.5 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market

9.5.1 Overview

9.5.2 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.3 South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.4 South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

9.5.5 South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

9.5.5.1 Brazil: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.2 Brazil: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.2.1 Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.5.2.2 Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

9.5.5.3 Argentina: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.3.1 Argentina: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.3.2 Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.5.3.3 Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

9.5.5.4 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.4.1 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

9.5.5.4.2 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

9.5.5.4.3 Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

10. Impact Of COVID-19 Pandemic on Chemotherapy Induced Peripheral Neuropathy Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

10.2 Europe: Impact Assessment of COVID-19 Pandemic

10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

10.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

10.5 South and Central America: Impact Assessment of COVID-19 Pandemic

11. Chemotherapy Induced Peripheral Neuropathy Market– Industry Landscape

11.1 Overview

11.2 Growth Strategies Done by the Companies in the Market, (%)

11.3 Organic Developments

11.3.1 Overview

11.4 Inorganic Developments

11.4.1 Overview

12. Company Profiles

12.1 REGENACY PHARMACEUTICALS, INC.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Asahi Kasei Pharma Corporation

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Novaremed AG

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 MAKScientific, LLC

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 WEX Pharmaceuticals Inc.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Sova Pharmaceuticals, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

12.7 Kineta, Inc.

12.7.1 Key Facts

12.7.2 Business Description

12.7.3 Products and Services

12.7.4 Financial Overview

12.7.5 SWOT Analysis

12.7.6 Key Developments

12.8 Aptinyx Inc.

12.8.1 Key Facts

12.8.2 Business Description

12.8.3 Products and Services

12.8.4 Financial Overview

12.8.5 SWOT Analysis

12.8.6 Key Developments

12.9 Apexian Pharmaceuticals, Inc.

12.9.1 Key Facts

12.9.2 Business Description

12.9.3 Products and Services

12.9.4 Financial Overview

12.9.5 SWOT Analysis

12.9.6 Key Developments

12.10 WinSanTor, Inc.

12.10.1 Key Facts

12.10.2 Business Description

12.10.3 Financial Overview

12.10.4 SWOT Analysis

12.10.5 Key Developments

13. Appendix

13.1 About The Insight Partners

13.2 Glossary of Terms


LIST OF TABLES

Table 1. North America Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 3. US Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 4. US Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 5. Canada: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 6. Canada Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 7. Mexico: Chemotherapy Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 8. Mexico Chemotherapy Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 9. Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 10. Europe Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 11. Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 12. Germany: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 13. France: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 14. France: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 15. UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 16. UK: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 17. Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 18. Italy: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 19. Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 20. Spain: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 21. Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 22. Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 23. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million).

Table 24. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 25. Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 26. Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 27. China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 28. China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 29. India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 30. India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 31. South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 32. South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 33. Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 34. Australia: Chemotherapy Induced Peripheral Neuropathy Market, by Sub-Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 35. Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Drug Class (US$ Million)

Table 36. Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Distribution Channel (US$ Million)

Table 37. Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Product (US$ Million)

Table 38. Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 39. UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 40. UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 41. Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 42. Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel– Revenue and Forecast to 2028 (US$ Million)

Table 43. South Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 44. South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 45. Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Drug Class (US$ Million)

Table 46. Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)

Table 47. South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 48. South and Central America Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 49. Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 50. Brazil Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 51. Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 52. Argentina Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 53. Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Drug Class– Revenue and Forecast to 2028 (USD Million)

Table 54. Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)

Table 55. Organic Developments Done By Companies

Table 56. Inorganic Developments Done By Companies

Table 57. Glossary of Terms

LIST OF FIGURES

Figure 1. Chemotherapy Induced Peripheral Neuropathy Market Segmentation

Figure 2. Chemotherapy Induced Peripheral Neuropathy Market, By Region

Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Market Overview

Figure 4. Steroids Segment Held Largest Share of Drug Class Segment in Chemotherapy Induced Peripheral Neuropathy Market

Figure 5. Asia Pacific is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. Chemotherapy Induced Peripheral Neuropathy Market, by Geography (US$ Million)

Figure 7. Global Chemotherapy Induced Peripheral Neuropathy Market - Leading Country Markets (US$ Million)

Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Market, Industry Landscape

Figure 9. North America: PEST Analysis

Figure 10. Europe: PEST Analysis

Figure 11. Asia Pacific: PEST Analysis

Figure 12. Middle East And Africa: PEST Analysis

Figure 13. South And Central America: PEST Analysis

Figure 14. Experts Opinion

Figure 15. Most Prevalent Forms of Cancers in the World, 2020

Figure 16. Impact Analysis of Drivers and Restraints Pertaining to Chemotherapy Induced Peripheral Neuropathy Market

Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Market– Revenue Forecast And Analysis – 2020- 2028

Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Market– Revenue Forecast And Analysis – 2021 - 2028

Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Market – Market Potential Analysis, By Region

Figure 20. Market Positioning Analysis Of Key Players In Global Chemotherapy Induced Peripheral Neuropathy Market

Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Market – Comparative Company Analysis

Figure 22. Global Chemotherapy Induced Peripheral Neuropathy Market – Growth Strategy Analysis

Figure 23. Drug Class Market Analysis and Forecast 2021 and 2028 (%)

Figure 24. Steroids Revenue and Forecast to 2028 (US$ Mn)

Figure 25. Antidepressants Revenue and Forecast to 2028 (US$ Mn)

Figure 26. Anti-seizure Revenue and Forecast to 2028 (US$ Mn)

Figure 27. Narcotics Revenue and Forecast to 2028 (US$ Mn)

Figure 28. Distribution Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 29. Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 30. Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 31. Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 32. North America: Chemotherapy Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (US$ Million)

Figure 33. North America Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

Figure 34. North America: Chemotherapy Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

Figure 35. US: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36. Canada: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37. Mexico: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38. Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (US$ Million)

Figure 39. Europe Chemotherapy- Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (US$ Million)

Figure 40. Europe: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

Figure 41. Germany: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 42. France: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 43. UK: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 44. Italy: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. Spain: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. Rest of Europe: Chemotherapy- Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Asia Pacific Chemotherapy Induced Peripheral Neuropathy Market Overview, by Country (2021)

Figure 48. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 49. Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028, By Country (%)

Figure 50. Japan: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 51. China: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 52. India: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 53. South Korea: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 54. Australia: Chemotherapy Induced Peripheral Neuropathy Market Revenue and Forecasts to 2028 (US$ Million)

Figure 55. Rest of Asia Pacific: Chemotherapy Induced Peripheral Neuropathy Market – Revenue and Forecast to 2028 (US$ Million)

Figure 56. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue Overview, by Country, 2021 (US$ Million)

Figure 57. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 58. Middle East & Africa Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028, by Country (%)

Figure 59. UAE: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 60. Saudi Arabia: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 61. South Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 62. Rest of Middle East & Africa: Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Revenue and Forecast to 2028 (US$ Million)

Figure 63. South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Key Country – Revenue (2021) (USD Million)

Figure 64. South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market Revenue and Forecast to 2028 (USD Million)

Figure 65. South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market, by Country, 2021 & 2028 (%)

Figure 66. Brazil: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

Figure 67. Argentina: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

Figure 68. Rest of South and Central America: Chemotherapy- Induced Peripheral Neuropathy Market– Revenue and Forecast to 2028 (USD Million)

Figure 69. Impact of COVID-19 Pandemic in North American Country Markets

Figure 70. Impact of COVID-19 Pandemic in European Country Markets

Figure 71. Impact of COVID-19 Pandemic in Asia Pacific Country Markets

Figure 72. Impact of COVID-19 Pandemic in Middle East & Africa Country Markets

Figure 73. Impact of COVID-19 Pandemic on Chemotherapy- Induced Peripheral Neuropathy Market in South and Central American Countries

Figure 74. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Chemotherapy Induced Peripheral Neuropathy Market

  1. REGENACY PHARMACEUTICALS, INC
  2. ASAHI KASEI PHARMA CORPORATION
  3. NOVAREMED
  4. MAKSCIENTIFIC, LLC
  5. WEX PHARMACEUTICALS INC
  6. SOVA PHARMACEUTICALS, INC
  7. KINETA, INC.
  8. APTINYX INC.
  9. APEXIAN PHARMACEUTICALS, INC.
  10. WINSANTOR, INC

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to Life Sciences : READ MORE..